What is Arkuda Therapeutics?
Arkuda Therapeutics is a biotechnology enterprise dedicated to transforming the treatment landscape for neurodegenerative conditions. The company focuses on lysosomal biology, specifically targeting progranulin deficiency and lysosomal dysfunction associated with GRN-related frontotemporal dementia. By developing small-molecule medicines that enhance the activity of key lysosomal enzymes, Arkuda aims to address the underlying pathology of complex neurological disorders, including Parkinson's disease. Its market position is defined by a rigorous scientific methodology that bridges the gap between fundamental genetic insights and actionable therapeutic solutions.
How much funding has Arkuda Therapeutics raised?
Arkuda Therapeutics has raised a total of $108M across 2 funding rounds:
Series A
$44M
Series B
$64M
Series A (2019): $44M with participation from BioInnovation Capital, Tekla Capital Management LLC, Atlas Venture, and Pfizer Ventures
Series B (2022): $64M led by Surveyor Capital, Lilly, Cormorant Asset Management, and Pivotal Bioventure Partners
Key Investors in Arkuda Therapeutics
Atlas Venture
Atlas Venture is a pioneering early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines.
Pfizer Ventures
Pfizer is a biopharmaceutical company that researches, develops, manufactures, and markets medicines and vaccines across multiple therapeutic areas.
Cormorant Asset Management
Cormorant Asset Management is a prominent life sciences investment firm driven by a deep focus on fundamental scientific principles and providing financial resources to support innovative biotech companies.
What's next for Arkuda Therapeutics?
With the recent capital injection, Arkuda Therapeutics is poised to transition its lead programs into more advanced stages of development. The strategic focus will likely center on scaling its internal research capabilities and advancing its pipeline of lysosomal-modulating compounds through preclinical and clinical milestones. As the company matures, it will continue to leverage its partnerships with leading life science investors to navigate the complexities of drug discovery and regulatory pathways. The emphasis remains on validating its therapeutic hypothesis in human populations, potentially establishing a new standard of care for patients suffering from rare and debilitating neurodegenerative diseases.
See full Arkuda Therapeutics company page
